Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
98
resultados
Última actualización
28/08/2026 [07:11:00]
Resultados 25 a 50 de 98
Resumen de: US20260234738A1
0000 The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Resumen de: US20260232749A1
A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt % total catechins, at least 20 wt % total chlorogenic acids, and optionally up to 30 wt % total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.
Resumen de: US20260234196A1
Disclosed in the present invention are a polypeptide and a polypeptide composition specifically binding to a SARS-CoV-2 spike protein, and preparation methods and the uses thereof. By means of binding to S1 protein, the polypeptide and the polypeptide composition can block the binding of SARS-CoV-2 virus to a key target protein angiotensin-converting enzyme 2 (ACE2) protein on the surface of a host cell thereof, thereby providing a feasible targeting drug for the treatment of Coronavirus disease 2019.
Resumen de: WO2025073771A1
The present invention inter alia relates to an use of an isolated polypeptide or an antigenic fragment thereof, comprising a polypeptide region having at least 60% sequence identity with any one of the polypeptide sequences selected from the group consisting of SEQ ID No.: 1-11, 16-20 and 23-28; wherein the isolated polypeptide is having a length of no more than 200 contiguous amino acids for diagnosing Long COVID or Post-Vac-Syndrome, or for predicting a risk of developing Long COVID or Post-Vac-Syndrome. The present invention also relates to the isolated polypeptide or antigenic fragment thereof for use in preventing, treating or ameliorating Long COVID or Post-Vac-Syndrome., as well as to a method of detecting a presence of antibodies against SARS-CoV-2 in a subject, comprising the step of contacting a sample of said subject with at least one of the polypeptide or antigenic fragment thereof.
Resumen de: EP4790065A1
Coronavirus spike protein variants for use in antigens for vaccines for coronavirus infection are provided.A coronavirus spike protein variant comprising:(a) a receptor binding domain (RBD) consisting of an amino acid sequence set forth in SEQ ID NO: 1;(b) an RBD consisting of an amino acid sequence obtained by substituting, deleting, inserting, or adding one to several amino acids in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of an RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1; or(c) an RBD consisting of an amino acid sequence that has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of the RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1.
Resumen de: US20260226034A1
0000 Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula
0000
0000 inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
Resumen de: US20260227400A1
0000 Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260227402A1
0000 Disclosed is a high-performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: AU2026206109A1
Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: , wherein the 1’ position of the nucleoside sugar is substituted. R¹ R¹¹¹ R¹ R³ X"" R² ul u l ¹ ²
Resumen de: AU2025218930A1
The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: US20260227401A1
Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Resumen de: US20260226140A1
Disclosed are a monoclonal antibody capable of rapidly, simply, and highly sensitively detecting and measuring SARS-CoV-2 contained in a test sample, and an immunoassay method and immunoassay device for SARS-CoV-2 using the same. The monoclonal antibody or its antigen-binding fragment includes heavy chain CDR1-CDR3 having specific amino acid sequences and light chain CDR1-CDR3 having specific amino acid sequences. The immunoassay method for SARS-CoV-2 includes performing an immunoassay of SARS-CoV-2 utilizing an antigen-antibody reaction between this monoclonal antibody or its antigen-binding fragment and SARS-CoV-2 in a sample.
Resumen de: WO2026163027A1
Provided herein is a replication-defective coronavirus having in its genome a modification, wherein the modification results in a reduced expression of the M gene compared to a coronavirus lacking the modification.
Resumen de: WO2026163139A1
The present disclosure relates to the use of β-lactoglobulin in the treatment of a viral condition, wherein β-lactoglobulin is in its native protein state, wherein the viral condition is caused by a human Rotavirus strain or Coronavirus OC43. The present disclosure further relates to a pharmaceutical composition comprising β-lactoglobulin and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.
Resumen de: AU2025219283A1
The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: US20260226425A1
An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that provides cold-adapted growth relative to a parent virus that is not cold-adapted and a vaccine comprising the recombinant genome and methods of using the vaccine are provided.
Resumen de: WO2026165023A1
The present disclosure is directed to antibodies binding to and neutralizing Middle East Respiratory Syndrome-Related Coronavirus (MERS-CoV) and methods for use thereof.
Resumen de: CN122029189A
The present invention provides antibodies that bind to the SARS-CoV-2 spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions and methods of using the above antibodies that bind to the SARS-CoV-2 spike (S) protein.
Resumen de: US20260216194A1
Disclosed herein are methods of treating a taste and smell disorder caused by a viral infection in a subject, comprising administering to the subject a phosphodiesterase inhibitor. Also disclosed herein are methods of treating taste and smell loss from COVID-19 by administering a phosphodiesterase inhibitor to a subject in need thereof.
Resumen de: AU2026205425A1
Abstract Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19. 5 Abstract ul b s t r a c t u l
Resumen de: US20260216253A1
The covid-19 coronavirus has killed more than 5,129,829 people, globally, out of about 255,098,687 infected. About 10 million persons died from cancer in 2020, with 19.3 new cases diagnosed. About 409,000 persons died of malaria in 2019. And none of these diseases made the WHO's list of top 5 deadly diseases of 2019. Modern medicine has made tremendous progress in the prevention and treatment of disease, but the crashing of the covid-19 coronavirus and the extremely high burden of the top deadly diseases point to the urgency of radical and totally disrupting inventions in medicine. Indeed, to effectively overcome the current burden of deadly diseases we need an agile platform with exponentially better efficacy and predictability. The world is in dire need of a new medicine platform that totally and radically disrupts the current healthcare systems and the traditional ways of preventing and treating disease. The present invention does that.The present invention uses transformed microbes, targeted to one or more mucosal surface, to prevent and treat just about any disease of importance. The current means of disease prevention relies on vaccines. As we have seen from countless failures and booster shots, vaccines have extreme limitations and increasingly fewer following. Firstly, vaccine development is unpredictable, lengthy and costly. An important lesson of the covid-19 pandemic is that waiting for several months or years to develop a vaccine, while a disease ravages the popul
Resumen de: US20260217797A1
Disclosed herein are antibodies that bind to coronavirus spike protein (e.g., SARS-CoV-2 spike protein), and methods of use thereof (e.g., treatment of subjects infected with SARSCoV-2).
Resumen de: US20260217840A1
The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.
Resumen de: US12695826B1
A voice amplifier that amplifies volume of a human voice from a microphone through a mobile device by utilizing a speaker that is communicably connected to the mobile device is disclosed. The voice amplifier is designed for a mobile device, such as a smart phone or a tablet computing device. The voice amplifier purely amplifies the voice from a wired or non-wired microphone through a phone operating system and hardware components and other modules of the mobile device, such as by utilizing the phone speaker and/or an optional wireless or wired speaker. Essentially through a voice amplifier mobile app, a voice can be amplified simply with the touch of one icon. The concept is for people wearing masks due to COVID-19 and future other viruses, and/or dusty, toxic, or otherwise unhealthy air environments where masks are needed, to continue to wear their mask but be able to communicate clearly.
Nº publicación: WO2026154387A1 23/07/2026
Solicitante:
NOVAVAX INC [US]
NOVAVAX, INC.
Resumen de: WO2026154387A1
Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains IgA antibodies against SARS-CoV-2 S glycoproteins. The method includes contacting a biological sample with a SARS-CoV-2 S glycoprotein-coated surface, contacting the surface with a secondary antibody, and detecting the secondary antibody, where if a secondary antibody is detected, the sample contains IgA antibodies against the SARS-CoV-2 S glycoprotein. Assay substrates and kits for performing such methods are also disclosed.
BOPI
Sede Electrónica
